Patents Assigned to The Board of Trustees of the Leland Stanford Junior University
-
Publication number: 20240124895Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: ApplicationFiled: December 5, 2022Publication date: April 18, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
-
Patent number: 11957787Abstract: Disclosed herein are methods, processes, compositions, and kits for generating bone graft materials for use at a site of bone defect that utilizes a composition which contains liposomal Wnt polypeptide, such as liposomal Wnt3a polypeptide, liposomal Wnt5a polypeptide, or liposomal Wnt10b polypeptide. Also disclosed herein are methods, processes, compositions, and kits for enhancing mammalian bone marrow cells that utilizes a composition which contains liposomal Wnt polypeptide, such as liposomal Wnt3a polypeptide, liposomal Wnt5a polypeptide, or liposomal Wnt10b polypeptide.Type: GrantFiled: September 22, 2020Date of Patent: April 16, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jill Helms, Girija Dhamdhere
-
Patent number: 11961837Abstract: In certain examples, methods and semiconductor structures are directed to an integrated circuit (IC) having a diamond layer section and a GaN-based substrate being monolithically integrated or bonded as part of the same IC. In a specific example, the GaN-based substrate includes GaN, AlxGayN (0<x<1; x+y=1) and a dielectric layer, and a diamond layer section which may include polycrystalline diamond. The IC includes: a GaN-based field effect transistor (FET) integrated with a portion of the GaN-based substrate, and a diamond-based FET integrated with a portion of the diamond layer section, the diamond FET being electrically coupled to the GaN-based FET and situated over or against a surface region of the GaN-based substrate.Type: GrantFiled: January 7, 2022Date of Patent: April 16, 2024Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Srabanti Chowdhury, Mohamadali Malakoutian, Matthew A. Laurent, Chenhao Ren, Siwei Li
-
Publication number: 20240120023Abstract: Methods for identifying biosynthetic gene clusters that include genes for producing compounds that interact with specific target proteins are disclosed. Some methods relate to bioinformatics methods for identifying and/or prioritizing biosynthetic gene clusters. Related systems, components, and tools for the identification and expression of such gene clusters are also disclosed.Type: ApplicationFiled: July 7, 2023Publication date: April 11, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Brian Thomas Naughton, Colin Harvey, Ulrich Schlecht, Maureen Elizabeth Hillenmeyer, Joe Horecka
-
Publication number: 20240115583Abstract: Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.Type: ApplicationFiled: May 15, 2023Publication date: April 11, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Adelaida R. Palla, Andrew Tri Van Ho
-
Patent number: 11953441Abstract: The disclosure provides an optical probe comprising an optical waveguide attached to a molecular switch that produces an altered optical signal upon binding a target molecule. The disclosure also provides an optical sensor system comprising an optical probe, a light source configured to emit the excitation light to be coupled into the optical waveguide of the optical probe; and a detector.Type: GrantFiled: October 23, 2019Date of Patent: April 9, 2024Assignees: CZ Biohub SF, LLC, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Amani Hariri, Constantin Dory, Alyssa Cartwright, Jelena Vuckovic, Hyongsok Tom Soh
-
Patent number: 11951619Abstract: Cable-actuated differential enabling N degrees of freedom provided by a plurality of pulleys and at least N+1 tensioning cables. The cable-actuated differential increases a dynamic force range by minimizing co-activation of the tensioning cables at any operating point. A cable-actuated differential having three cables provides motor based control of a 2 DOF joint that can be applied to robots or teleoperation. A cable-actuated mechanical differential having opposing bevel gears and a middle bevel gear meshed with the opposing gear allows an output connector to controllably and independently rotate about the x axis or y axis via three operational modes without backlash.Type: GrantFiled: April 25, 2018Date of Patent: April 9, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: J. Kenneth Salisbury, Jr., Alex Nathan Kahn
-
Patent number: 11955646Abstract: A supported catalyst includes: (1) a catalyst support; and (2) deposits of a catalyst covering the catalyst support, wherein the deposits have an average thickness of about 2 nm or less, and the deposits are spaced apart from one another.Type: GrantFiled: November 7, 2018Date of Patent: April 9, 2024Assignees: The Board of Trustees of the Leland Stanford Junior University, Volkswagen AktiengesellschaftInventors: Friedrich B. Prinz, Thomas Jaramillo, Drew C. Higgins, Yongmin Kim, Shicheng Xu, Thomas Schladt, Tanja Graf
-
Patent number: 11951630Abstract: Systems and methods of the present disclosure provide a control solution for a robotic actuator. The actuator can have one or two degrees of freedom of control, and can connect with a platform using an arm. The arm can have at least two degrees of freedom of control, and the platform can have at least two degrees of freedom of control. The platform can be subjected to unpredictable forces requiring a control response. The control solution can be generated using operational space control, using the degrees of freedom of the arm, platform and actuator.Type: GrantFiled: April 23, 2021Date of Patent: April 9, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Oussama Khatib
-
Patent number: 11951149Abstract: Provided herein are methods for treating, reducing and/or ameliorating symptoms of autism spectrum disorder (ASD) in a subject, where at least one measure of social impairment, anxiety, or repetitive behaviors is treated and/or ameliorated. Aspects include intranasally administering arginine vasopressin (AVP), or an analog of vasopressin, to a subject (e.g., a child between 6 and 12 years of age and having endogenous pre-treatment levels between about 0.045 and about 4.028 pg/mL, where the mean was 1.324 pg/mL). In children having high pre-treatment blood levels of AVP (e.g., about 25% or more above the mean pre-treatment AVP blood levels of the treatment group; or having pre-treatment blood vasopressin levels greater than 1.324 pg/mL), the treatment was enhanced. Because no difference in pre-treatment blood AVP levels was observed between control and ASD subjects, it was surprising that AVP treatment was more effective in subjects having high pre-treatment AVP levels.Type: GrantFiled: July 10, 2019Date of Patent: April 9, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Karen J. Parker, Dean S. Carson, Antonio Y. Hardan
-
Patent number: 11952588Abstract: The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.Type: GrantFiled: February 7, 2019Date of Patent: April 9, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Everett H. Meyer, Robert S. Negrin
-
Patent number: 11952570Abstract: Methods are provided for the isolation and analysis of circular DNA from complex samples, based on the topology of the DNA molecule. A sample comprising DNA species is combined with a chaotropic dense salt solution. A fraction containing the circular DNA of interest is isolated and dialyzed to remove excess salt. In some embodiments salt gradients are generated by ultracentrifugation in the absence of intercalating dyes, e.g. ethidium bromide; and in the absence of protease digestion. The circular DNA thus isolated is substantially pure, e.g. greater than about 75%, greater than about 80%, greater than about 90%, greater than about 95% of DNA in the isolated fraction is comprised of circular DNA.Type: GrantFiled: January 18, 2023Date of Patent: April 9, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Massa Shoura, Stephen Levene, David Girata
-
Patent number: 11951187Abstract: The disclosure provides NIR-II imaging probes and methods of using the NIR-II imaging probes for dynamic in vivo tracking of cells, such as stem cells, or other substances. NIR-II imaging probes can include a biocompatible NIR-II dye molecule coupled to an organic, biocompatible protein carrier complex, including a carrier protein coupled to a cell-penetrating peptide.Type: GrantFiled: February 19, 2021Date of Patent: April 9, 2024Assignee: The Board of Trustees of Leland Stanford Junior UniversityInventors: Zhen Cheng, Hao Chen
-
Patent number: 11946821Abstract: Aspects of various embodiments are directed to sensor apparatuses and methods thereof. An example sensor apparatus includes a capacitor and sensor circuitry. The capacitor includes a first substrate having a first electrode, a second substrate having a second electrode, and a dielectric layer. The dielectric layer has a plurality of apertures arranged in a pattern, the first and second electrode being separated by the dielectric layer and arranged with an overlapping area with respect to one another. The sensor circuitry is coupled to the capacitor and configured and arranged to detect normal and shear forces applied to the sensor apparatus based on changes in capacitance derived from changes in at least one of a distance between the first and second electrodes and the overlapping area of the first and second electrodes.Type: GrantFiled: July 10, 2019Date of Patent: April 2, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Zhenan Bao, Mark R. Cutkosky, Jooyeun Ham
-
Patent number: 11948676Abstract: A method for quantitative magnetic resonance imaging (MRI) includes [800] performing an MRI scan using a conventional pulse sequence to obtain a qualitative MR image; and [802] applying the qualitative MR image as input to a deep convolutional neural network (CNN) to produce a quantitative magnetic resonance (MR) relaxation parametric map. The qualitative MR image is the only image input to the deep neural network to produce the quantitative MR relaxation parametric map. The conventional pulse sequence may be a Spoiled Gradient Echo sequence, a Fast Spin Echo sequence, a Steady-State Free Precession sequence, or other sequence that is commonly used in current clinical practice.Type: GrantFiled: December 12, 2019Date of Patent: April 2, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lei Xing, Yan Wu
-
Patent number: 11945112Abstract: Simulated motion of the papillary muscles in a heart simulator is provided that simulates natural motion of the papillary muscles. This improves heart valve simulation. This can be done with a six degree of freedom robotic actuator (e.g., a Stewart platform or the like) appropriately driven by a controller. This can also be done with a robotic actuator that provides constrained motion of its effector by including a mechanical linkage, as long as the resulting simulated papillary muscle motion includes time-varying position and orientation of the papillary muscle.Type: GrantFiled: March 1, 2021Date of Patent: April 2, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Y. Joseph Woo, Michael John Paulsen, Annabel M. Imbrie-Moore, Matthew Park, Rohun Kulkarni
-
Publication number: 20240102022Abstract: Methods and compositions are provided for the treatment of Alzheimer's Disease (AD) by administering to a patient a therapeutically effective amount of an agent that inhibits signaling mediated by a bone morphogenetic protein type 1A receptor (BMPR-1A) or bone morphogenetic protein type 2 receptor (BMPR-2). Also provided are methods and compositions to increase the rate of neural stem cell self-renewal.Type: ApplicationFiled: November 17, 2023Publication date: March 28, 2024Applicants: CZ Biohub SF, LLC, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Elizabeth Yang Chen, Felicia Reinitz, Jane Antony, Michael F. Clarke, Robert C. Jones
-
Publication number: 20240100061Abstract: Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or after the iboga alkaloid.Type: ApplicationFiled: September 14, 2023Publication date: March 28, 2024Applicants: The Board of Trustees of the Leland Stanford Junior University, Soneira Inc., P.B.C.Inventors: Nolan R. Williams, Ian Kratter, AnnaMarie Daniels, Gregory Bird
-
Publication number: 20240102030Abstract: Inducible promoters for the coordinated expression of at least one heterologous gene in yeast and methods of using them are disclosed. In particular, the invention relates to sets of inducible promoters derived from S. cerevisiae and related species that can be induced in the presence of nonfermentable carbon sources.Type: ApplicationFiled: September 6, 2023Publication date: March 28, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Colin Harvey, Ulrich Schlecht, Maureen Elizabeth Hillenmeyer
-
Publication number: 20240105281Abstract: Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, nucleic acid molecules, such as cell-free nucleic acids, can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and/or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.Type: ApplicationFiled: August 18, 2023Publication date: March 28, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jacob J. Chabon, David M. Kurtz, Maximilian Diehn, Arash Ash Alizadeh